Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection.
作者信息
Owusu-Boaitey Nana
机构信息
Fischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
出版信息
Microbiol Spectr. 2025 Feb 4;13(2):e0155824. doi: 10.1128/spectrum.01558-24. Epub 2024 Dec 16.
Abstract
摘要
相似文献
1
Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection.疫苗接种导致对SARS-CoV-2感染累积发病率的低估。
Microbiol Spectr. 2025 Feb 4;13(2):e0155824. doi: 10.1128/spectrum.01558-24. Epub 2024 Dec 16.
2
Reply to "Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection".对《疫苗接种导致严重急性呼吸综合征冠状病毒2感染累计发病率估计偏低》的回复
Microbiol Spectr. 2025 Feb 4;13(2):e0197924. doi: 10.1128/spectrum.01979-24. Epub 2024 Dec 16.
3
Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore.新加坡 SARS-CoV-2 感染与 mRNA SARS-CoV-2 疫苗接种后颅内静脉血栓形成的发生率。
JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940.
4
Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies.根据抗体衰减情况估计 SARS-CoV-2 感染的累积发病率和感染病死率。
Epidemiology. 2021 Jul 1;32(4):518-524. doi: 10.1097/EDE.0000000000001361.
5
Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies.鉴于抗体水平下降，估算新型冠状病毒2型（SARS-CoV-2）感染的累积发病率和感染致死率。
medRxiv. 2020 Nov 16:2020.11.13.20231266. doi: 10.1101/2020.11.13.20231266.
6
Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study.用于测量 SARS-CoV-2 感染和疫苗免疫反应的检测方法协调研究：血清学方法研究。
Microbiol Spectr. 2023 Jun 15;11(3):e0535322. doi: 10.1128/spectrum.05353-22. Epub 2023 May 16.
7
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.2021 年 8 月至 10 月，BNT162b2 疫苗第三剂接种与长期护理机构居民 SARS-CoV-2 感染、COVID-19 相关住院和死亡的相关性。
JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940.
8
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses.商业平台检测到的 SARS-CoV-2 血清学状态可区分既往感染和疫苗接种的适应性免疫反应。
J Appl Lab Med. 2021 Sep 1;6(5):1109-1122. doi: 10.1093/jalm/jfab080.
9
Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection.自然感染和疫苗诱导的免疫对于预防 SARS-CoV-2 感染的效果相当。
J Infect Public Health. 2023 Aug;16(8):1137-1141. doi: 10.1016/j.jiph.2023.05.018. Epub 2023 May 20.
10
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina.在阿根廷接受严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种且正在接受高效疗法治疗的多发性硬化症患者中SARS-CoV-2感染的发生率。
Neurol Sci. 2024 Feb;45(2):379-389. doi: 10.1007/s10072-023-07282-x. Epub 2023 Dec 30.
本文引用的文献
1
Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.检测未接种疫苗和接种疫苗的献血者中与原发性 SARS-CoV-2 感染相关的核衣壳抗体。
Emerg Infect Dis. 2024 Aug;30(8):1621-1630. doi: 10.3201/eid3008.240659. Epub 2024 Jul 9.
2
Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021.2021年9月至12月美国商业实验室血清标本与献血者标本中新冠病毒血清流行率估计值的比较
Microbiol Spectr. 2024 Aug 6;12(8):e0012324. doi: 10.1128/spectrum.00123-24. Epub 2024 Jun 13.
3
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.SARS-CoV-2 血清学检测敏感性的动态变化：系统评价和模型研究。
Euro Surveill. 2023 May;28(21). doi: 10.2807/1560-7917.ES.2023.28.21.2200809.
4
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.当估计美国 SARS-CoV-2 血清流行率的时间动态时，要考虑检测性能。
Nat Commun. 2023 Apr 19;14(1):2235. doi: 10.1038/s41467-023-37944-5.
5
Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants.奥密克戎变异株流行期间抗SARS-CoV-2核衣壳蛋白抗体对突破性感染的敏感性。
J Infect. 2022 Nov;85(5):573-607. doi: 10.1016/j.jinf.2022.08.015. Epub 2022 Aug 20.
6
Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort.病毒学确诊的 SARS-CoV-2 感染后的核衣壳和刺突抗体反应：病毒观察社区队列的观察性分析。
Int J Infect Dis. 2022 Oct;123:104-111. doi: 10.1016/j.ijid.2022.07.053. Epub 2022 Aug 18.
7
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.SARS-CoV-2 感染后抗核衣壳抗体在随机、安慰剂对照的 mRNA-1273 COVID-19 疫苗疗效临床试验的盲法阶段。
Ann Intern Med. 2022 Sep;175(9):1258-1265. doi: 10.7326/M22-1300. Epub 2022 Jul 5.
8
Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals.新型冠状病毒2型（SARS-CoV-2）感染的血清学标志物；抗核衣壳抗体阳性可能不是疫苗接种个体自然感染的理想标志物。
J Infect. 2021 Oct;83(4):e9-e10. doi: 10.1016/j.jinf.2021.08.012. Epub 2021 Aug 9.
Zotero 插件